成人先天性心脏病患者肺动脉位置生物瓣膜的结局
该回顾性研究纳入1990至2017年Mayo Clinic的573例成人先天性心脏病患者共807枚肺动脉位置生物瓣膜,评估瓣膜功能障碍(PVD)发生率及影响因素。结果显示PVD发生率为33%,15年累积发生率为48%,人工瓣膜类型与PVD无关,而心房颤动史和右心室功能不全增加PVD风险,术后维生素K拮抗剂抗凝与较低PVD风险相关。
要点
- 肺动脉位置生物瓣膜远期耐久性有限,15年累积PVD发生率达48%。
- 心房颤动史和大于中度右心室功能不全是PVD的独立危险因素。
- 术后维生素K拮抗剂抗凝可能与降低PVD风险相关。
核心结论
- 肺动脉位置生物瓣膜耐久性有限,需关注终生再干预累积风险。
- 需前瞻性研究明确治疗心房颤动和术后抗凝能否延迟PVD发生。
研究设计与样本
- 回顾性研究,纳入1990至2017年Mayo Clinic的573例成人先天性心脏病患者,共807枚肺动脉位置生物瓣膜。
- 研究终点PVD定义为峰值流速大于4 m/s、严重人工瓣膜反流或两者兼有。
主要发现
- 267枚(33%)人工瓣膜发生PVD。
- PVD发生时间为12.6±3.9年,发生率为3.2例/100瓣膜年(95%CI 3.0-3.4),15年累积发生率为48%(95%CI 43%-53%)。
- 不同人工瓣膜类型间耐久性无差异。
关键数值与推荐
- PVD定义:峰值流速大于4 m/s、严重人工瓣膜反流或两者兼有。
临床怎么用
- 对肺动脉位置生物瓣膜患者应长期随访,关注PVD发生。
- 合并心房颤动或右心室功能不全者可能需更密切监测。
- 术后维生素K拮抗剂抗凝对PVD的预防作用需前瞻性研究验证。
局限性
- 回顾性研究设计。
- 单中心研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There are limited data on the incidence of prosthetic valve dysfunction (PVD) after pulmonary valve replacement (PVR). The purpose of this study was to determine the longevity of bioprosthetic valves in the pulmonary position and the factors associated with bioprosthetic valve longevity in adults with congenital heart disease. METHODS: This retrospective review of adults with bioprosthetic PVR was conducted at the Mayo Clinic in Rochester, Minnesota from 1990 to 2017. The study end point was PVD, defined as peak velocity greater than 4 m/s, severe prosthetic regurgitation, or both. For the purpose of this study we assessed bioprosthetic valve longevity by using 3 different indices: (1) cumulative incidence of PVD, (2) incidence density of PVD, and (3) time to PVD. RESULTS: There were 807 bioprosthetic PVRs in 573 patients. PVD occurred in 267 (33%) prostheses. Time to PVD was 12.6 ± 3.9 years, the incidence of PVD was 3.2 (95% confidence interval [CI], 3.0 to 3.4) cases per 100 prosthesis-years, and the 15-year cumulative incidence was 48% (95% CI, 43%- to 53%). No difference in prosthesis longevity by type of prosthesis implanted was observed. The multivariate risk factors for PVD were a history of atrial fibrillation (hazard ratio [HR], 1.36; 95% CI, 1.08 to 2.54; P = .014), and greater than moderate right ventricular dysfunction (HR, 1.21, 95% CI, 1.01 to 1.48; P = .049). Postoperative anticoagulation with a vitamin K antagonist was associated with a lower risk of PVD (HR, 0.83; 95% CI, 0.61 to 0.92; P = .038). CONCLUSIONS: The limited longevity of bioprosthetic valves poses significant concerns about the cumulative lifetime risk of reinterventions. Prospective studies are required to determine if interventions such as treatment of atrial fibrillation and postoperative anticoagulation will delay the occurrence of PVD.
引用
- Egbe AC, Connolly HM, Miranda WR, et al. Outcomes of Bioprosthetic Valves in the Pulmonary Position in Adults With Congenital Heart Disease. Ann Thorac Surg. 2019. PMID: 31323213. doi:10.1016/j.athoracsur.2019.05.068
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。